Status:
ACTIVE_NOT_RECRUITING
PRedictiOn Algorithms for the DeTECTion of Early Stage Pancreatic Cancer
Lead Sponsor:
Kaiser Permanente
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
Eligibility:
All Genders
50-84 years
Brief Summary
Conduct a prospective study to assess the accuracy of a pancreatic cancer risk prediction model.
Detailed Description
The goal of this study is to establish a platform for development and implementation of a data-driven risk model for detection of early stage pancreatic cancer within an integrated health care setting...
Eligibility Criteria
Inclusion
- Patient must have 6 months of membership
- Patient has a measure for weight, Hemoglobin A1C, and Alanine transaminase (ALT) within the past 6 months
- Patient must have an increased predicted 18-month risk of pancreatic cancer based on the PRO-TECT model
- Speaks English or Spanish
Exclusion
- Previous or current history of pancreatic cancer
- Metastatic cancer
- Current active cancer or undergoing chemotherapy for cancer
- Currently pregnant or breastfeeding
- Class IV heart failure
- Cirrhosis with ascites and/or varices
- Currently in a skilled nursing facility or under hospice care
- Has metal parts or implanted devices in the body, such as a pacemaker, defibrillator, or shrapnel
- End stage renal disease
- Cognitive impairment such that the person is unable to provide informed consent
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2025
Estimated Enrollment :
126 Patients enrolled
Trial Details
Trial ID
NCT04883450
Start Date
February 1 2021
End Date
June 30 2025
Last Update
January 16 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kaiser Permanente Southern California
Pasadena, California, United States, 91101